Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 108
Filter
1.
J Affect Disord ; 314: 176-184, 2022 10 01.
Article in English | MEDLINE | ID: mdl-35777494

ABSTRACT

BACKGROUND: Reward system dysfunction is evident across neuropsychiatric conditions. Here we present data from a double-blinded pharmaco-fMRI study investigating the triggering of anhedonia and reward circuit activity in women. METHODS: The hormonal states of pregnancy and parturition were simulated in euthymic women with a history of postpartum depression (PPD+; n = 15) and those without such a history (PPD-; n = 15) by inducing hypogonadism, adding back estradiol and progesterone for 8 weeks ("addback"), and then withdrawing both steroids ("withdrawal"). Anhedonia was assessed using the Inventory of Depression and Anxiety Symptoms (IDAS) during each hormone phase. Those who reported a 30 % or greater increase in IDAS anhedonia, dysphoria, or ill temper during addback or withdrawal, compared with pre-treatment, were identified as hormone sensitive (HS+) and all others were identified as non-hormone sensitive (HS-). The monetary incentive delay (MID) task was administered during fMRI sessions at pre-treatment and during hormone withdrawal to assess brain activation during reward anticipation and feedback. RESULTS: On average, anhedonia increased during addback and withdrawal in PPD+ but not PPD-. During reward feedback, both HS+ (n = 10) and HS- (n = 18) showed decreased activation in clusters in the right putamen (p < .031, FWE-corrected) and left postcentral and supramarginal gyri (p < .014, FWE-corrected) at the withdrawal scans, relative to pre-treatment scans. LIMITATIONS: A modest sample size, stringent exclusion criteria, and relative lack of diversity in study participants limit the generalizability of results. CONCLUSION: Although results do not explain differential hormone sensitivity in depression, they demonstrate significant effects of reproductive hormones on reward-related brain function in women.


Subject(s)
Anhedonia , Depression, Postpartum , Anhedonia/physiology , Brain/diagnostic imaging , Brain Mapping , Depression, Postpartum/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Pregnancy , Reward
2.
Trials ; 22(1): 186, 2021 Mar 05.
Article in English | MEDLINE | ID: mdl-33673867

ABSTRACT

BACKGROUND: Depression and anxiety impact up to 1 in 5 pregnant and postpartum women worldwide. Yet, as few as 20% of these women are treated with frontline interventions such as evidence-based psychological treatments. Major barriers to uptake are the limited number of specialized mental health treatment providers in most settings, and problems with accessing in-person care, such as childcare or transportation. Task sharing of treatment to non-specialist providers with delivery on telemedicine platforms could address such barriers. However, the equivalence of these strategies to specialist and in-person models remains unproven. METHODS: This study protocol outlines the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) randomized trial. SUMMIT is a pragmatic, non-inferiority test of the comparable effectiveness of two types of providers (specialist vs. non-specialist) and delivery modes (telemedicine vs. in-person) of a brief, behavioral activation (BA) treatment for perinatal depressive and anxiety symptoms. Specialists (psychologists, psychiatrists, and social workers with ≥ 5 years of therapy experience) and non-specialists (nurses and midwives with no formal training in mental health care) were trained in the BA protocol, with the latter supervised by a BA expert during treatment delivery. Consenting pregnant and postpartum women with Edinburgh Postnatal Depression Scale (EPDS) score of ≥ 10 (N = 1368) will be randomized to one of four arms (telemedicine specialist, telemedicine non-specialist, in-person specialist, in-person non-specialist), stratified by pregnancy status (antenatal/postnatal) and study site. The primary outcome is participant-reported depressive symptoms (EPDS) at 3 months post-randomization. Secondary outcomes are maternal symptoms of anxiety and trauma symptoms, perceived social support, activation levels and quality of life at 3-, 6-, and 12-month post-randomization, and depressive symptoms at 6- and 12-month post-randomization. Primary analyses are per-protocol and intent-to-treat. The study has successfully continued despite the COVID-19 pandemic, with needed adaptations, including temporary suspension of the in-person arms and ongoing randomization to telemedicine arms. DISCUSSION: The SUMMIT trial is expected to generate evidence on the non-inferiority of BA delivered by a non-specialist provider compared to specialist and telemedicine compared to in-person. If confirmed, results could pave the way to a dramatic increase in access to treatment for perinatal depression and anxiety. TRIAL REGISTRATION: ClinicalTrials.gov NCT04153864 . Registered on November 6, 2019.


Subject(s)
Anxiety/therapy , Depression, Postpartum/therapy , Depression/therapy , Health Services Accessibility , Pregnancy Complications/therapy , Psychotherapy/methods , Telemedicine/methods , COVID-19 , Delivery of Health Care/methods , Equivalence Trials as Topic , Female , Humans , Maternal Health Services , Mental Health Services/organization & administration , Midwifery , Nurses , Pragmatic Clinical Trials as Topic , Pregnancy , Psychiatric Status Rating Scales , Psychiatry , Psychology , SARS-CoV-2 , Social Workers , Specialization
3.
Exp Cell Res ; 362(2): 349-361, 2018 01 15.
Article in English | MEDLINE | ID: mdl-29208460

ABSTRACT

RalGPS2 is a Ras-independent Guanine Nucleotide Exchange Factor (GEF) for RalA containing a PH domain and an SH3-binding region and it is involved in several cellular processes, such as cytokinesis, control of cell cycle progression, differentiation, cytoskeleton organization and rearrangement. Up to now, few data have been published regarding RalGPS2 role in cancer cells, and its involvement in bladder cancer is yet to be established. In this paper we demonstrated that RalGPS2 is expressed in urothelial carcinoma-derived 5637 cancer cells and is essential for cellular growth. These cells produces thin membrane protrusions that displayed the characteristics of actin rich tunneling nanotubes (TNTs) and here we show that RalGPS2 is involved in the formation of these cellular protrusions. In fact the overexpression of RalGPS2 or of its PH-domain increased markedly the number and the length of nanotubes, while the knock-down of RalGPS2 caused a strong reduction of these structures. Moreover, using a series of RalA mutants impaired in the interaction with different downstream components (Sec5, Exo84, RalBP1) we demonstrated that the interaction of RalA with Sec5 is required for TNTs formation. Furthermore, we found that RalGPS2 interacts with the transmembrane MHC class III protein leukocyte specific transcript 1 (LST1) and RalA, leading to the formation of a complex which promotes TNTs generation. These findings allow us to add novel elements to molecular models that have been previously proposed regarding TNTs formation.


Subject(s)
Guanine Nucleotide Exchange Factors/genetics , Nanotubes , Urinary Bladder Neoplasms/genetics , ral GTP-Binding Proteins/genetics , Animals , Cell Differentiation/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Intracellular Signaling Peptides and Proteins , Membrane Proteins/genetics , Pleckstrin Homology Domains/genetics , Urinary Bladder Neoplasms/pathology , Vesicular Transport Proteins/genetics , src Homology Domains/genetics
4.
J Dent Res ; 96(10): 1153-1161, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28489485

ABSTRACT

Eph receptors belong to a subfamily of receptor tyrosine kinases that are activated by membrane-spanning ligands called ephrins. Previously, we demonstrated that the ephrinB1-EphB2 interaction regulates odontogenic/osteogenic differentiation from dental pulp cells (DPCs) in vitro. The goal of this study was to identify the molecular mechanisms regulated by the EphB2/ephrinB1 system that govern tertiary dentin formation in vitro and in vivo. During tooth development, ephrinB1, and EphB2 were expressed in preodontoblast and odontoblasts at postnatal day 4. EphrinB1 was continuously expressed in odontoblasts and odontoblastic processes until the completion of tooth eruption. In addition, ephrinB1 was expressed in odontoblastic processes 2 wk following tooth injury without pulp exposure, whereas EphB2 was expressed in the center of pulp niches but not odontoblasts. In a model of tooth injury with pulp exposure, ephrinB1 was strongly expressed in odontoblasts 4 wk postinjury. In vitro studies with human and mouse DPCs treated with calcium hydroxide (CH) or mineral trioxide aggregate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1). Experiments using several inhibitors of IGF-1 receptor signaling revealed that inhibiting the Ras/Raf-1/MAPK pathway inhibited EphB2 expression, and inhibiting the PI3K/Akt/mTOR pathway specifically inhibited ephrinB1 gene expression. Tooth injury in mice with odontoblast-specific IGF-1 receptor ablation exhibited a reduced tertiary dentin volume, mineral density, and ephrinB1 expression 4 wk following injury. We conclude that the IGF-1/ephrinB1 axis plays significant roles in the early stages of tooth injury. Further research is needed to fully understand the potential of targeting ephrinB1 as a regenerative pulp therapy.


Subject(s)
Dentin/metabolism , Dentinogenesis/physiology , Ephrin-B1/metabolism , Insulin-Like Growth Factor I/metabolism , Odontoblasts/metabolism , Aluminum Compounds/pharmacology , Animals , Calcium Compounds/pharmacology , Calcium Hydroxide/pharmacology , Dental Pulp/metabolism , Drug Combinations , Humans , Male , Mice , Mice, Inbred C57BL , Models, Animal , Oxides/pharmacology , Signal Transduction , Silicates/pharmacology
5.
J Geophys Res Atmos ; 119(4): 1915-1935, 2014 Feb 27.
Article in English | MEDLINE | ID: mdl-28845379

ABSTRACT

Acquiring accurate measurements of water vapor at the low mixing ratios (< 10 ppm) encountered in the upper troposphere and lower stratosphere (UT/LS) has proven to be a significant analytical challenge evidenced by persistent disagreements between high-precision hygrometers. These disagreements have caused uncertainties in the description of the physical processes controlling dehydration of air in the tropical tropopause layer and entry of water into the stratosphere and have hindered validation of satellite water vapor retrievals. A 2011 airborne intercomparison of a large group of in situ hygrometers onboard the NASA WB-57F high-altitude research aircraft and balloons has provided an excellent opportunity to evaluate progress in the scientific community toward improved measurement agreement. In this work we intercompare the measurements from the Midlatitude Airborne Cirrus Properties Experiment (MACPEX) and discuss the quality of agreement. Differences between values reported by the instruments were reduced in comparison to some prior campaigns but were nonnegligible and on the order of 20% (0.8 ppm). Our analysis suggests that unrecognized errors in the quantification of instrumental background for some or all of the hygrometers are a likely cause. Until these errors are understood, differences at this level will continue to somewhat limit our understanding of cirrus microphysical processes and dehydration in the tropical tropopause layer.

6.
Brain Stimul ; 5(3): 242-251, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21962978

ABSTRACT

BACKGROUND: Anodal transcranial direct current stimulation (tDCS) of the prefrontal cortex has been proposed as therapeutic intervention in major depression. According to clinical needs, this study addresses the question whether tDCS is effective in treatment resistant major depressive episodes. METHODS: Twenty-two patients with a major depressive episode were randomly assigned to a cross-over protocol comparing tDCS and placebo stimulation add-on to a stable antidepressant medication. The parameters of active tDCS were: 1 or 2 mA for 20 minutes/day, anode over the left dorsolateral prefrontal cortex, cathode over the contralateral supraorbital region. Active and placebo tDCS was applied for 2 weeks using indistinguishable DC stimulators. Patients, raters, and operators were blinded to treatment conditions. RESULTS: There was no significant difference in depression scores after 2 weeks of real compared with 2 weeks of sham tDCS. Scores on the Hamilton Depression Rating Scale were reduced from baseline by 14.7% for active tDCS and 10% for placebo tDCS. In contrast, subjective mood ratings showed an increase in positive emotions after real tDCS compared with sham tDCS. CONCLUSIONS: Anodal tDCS, applied for 2 weeks, was not superior to placebo treatment in patients with treatment resistant depression. However, secondary outcome measures are pointing to a positive effect of tDCS on emotions. Therefore, modified and improved tDCS protocols should be carried out in controlled pilot trials to develop tDCS towards an efficacious antidepressant intervention in therapy-resistant depression.


Subject(s)
Depression/diagnosis , Depression/prevention & control , Transcranial Magnetic Stimulation/methods , Adult , Aged , Chronic Disease , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Middle Aged , Placebo Effect , Treatment Outcome
7.
J Econ Entomol ; 102(1): 20-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19253613

ABSTRACT

Three almond field trials were conducted during 2003 and 2004 at two locations in central (Fresno County) and northern (Yolo County) California to evaluate the potential effects of commercial applications of Captan on honey bees, Apis mellifera L. Captan was applied at 5.0 kg (AI)/ha during bloom. Hives were evaluated for hive health and brood development parameters for approximately 2 mo after application. This study showed that the application of Captan was not harmful to foraging honey bees or their brood. No treatment-related effects were noted on hive weights, dead bee deformity, number of dead bees, survival of individual larvae, weight of individual emerging adults, and other hive health parameters.


Subject(s)
Bees/drug effects , Captan/pharmacology , Fungicides, Industrial/pharmacology , Pesticide Residues/analysis , Agriculture , Animals , Bees/growth & development , Body Weight/drug effects , California , Captan/analysis , Flowers/chemistry , Fungicides, Industrial/analysis , Honey/analysis , Prunus/chemistry , Weather
8.
Oncogene ; 27(46): 6068-74, 2008 Oct 09.
Article in English | MEDLINE | ID: mdl-18574467

ABSTRACT

The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha synergistically upregulated FAT10 expression in liver and colon cancer cells 10- to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-gamma- and TNF-alpha-dependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.


Subject(s)
Carcinoma, Hepatocellular/genetics , Carcinoma/genetics , Colonic Neoplasms/genetics , Cytokines/pharmacology , Inflammation Mediators/pharmacology , Liver Neoplasms/genetics , Ubiquitins/genetics , Up-Regulation/drug effects , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cells, Cultured , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Humans , Mice , Mice, Inbred C57BL , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Tissue Distribution/drug effects , Ubiquitins/metabolism
9.
Aliment Pharmacol Ther ; 22(10): 971-9, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16268972

ABSTRACT

AIM: The gastrointestinal transit of sequentially administered capsules was investigated in relation to the availability of fluid along the intestinal lumen by magnetic resonance imaging. METHODS: Water-sensitive magnetic resonance imaging was performed on 12 healthy subjects during fasting and 1 h after a meal. Specifiable non-disintegrating capsules were administered at 7, 4 and 1 h prior to imaging. RESULTS: While food intake reduced the mean fluid volumes in the small intestine (105 +/- 72 mL vs. 54 +/- 41 mL, P < 0.01) it had no significant effect on the mean fluid volumes in the colon (13 +/- 12 mL vs. 18 +/- 26 mL). The mean number of separated fluid pockets increased in both organs after meal (small intestine: 4 vs. 6, P < 0.05; large intestine: 4 vs. 6, P < 0.05). The distribution of capsules between the small and large intestine was strongly influenced by food (colon: 3 vs. 17 capsules, P < 0.01). CONCLUSIONS: The results show that fluid is not homogeneously distributed along the gut, which likely contributes to the individual variability of drug absorption. Furthermore, transport of fluid and solids through the ileocaecal valve is obviously initiated by a meal-induced gastro-ileocaecal reflex.


Subject(s)
Body Water/physiology , Gastrointestinal Transit/physiology , Adult , Capsules , Colon/metabolism , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged
10.
Biomed Tech (Berl) ; 47 Suppl 1 Pt 1: 488-91, 2002.
Article in German | MEDLINE | ID: mdl-12451902

ABSTRACT

For the reconstruction of complex skull defects with individual prefabricated CAD/CAM-implants titanium is well established as bone substitution material. The aim of our studies was to optimize a composite material from polyesters and calcium phosphate. Therefore two different operating procedures (hot pressing and gas-flushing) were combined. As a result the graded composition and porosity of the implants allow a spatial guided degradation progress and cell ingrowth. First biocompatibility tests in vitro with primary human osteoblasts showed a much better pH-characteristic and a better biocompatibility of the composites in comparison with the pure polymers. Degradation experiments in vitro confirmed the different expected degradation rates of the composite materials. As a next step in vivo experiments in ovine skulls are in progress.


Subject(s)
Biocompatible Materials , Calcium Phosphates , Computer-Aided Design , Craniotomy/methods , Lactic Acid , Polyesters , Polyglycolic Acid , Polymers , Prosthesis Implantation , Animals , Cell Division/physiology , Cells, Cultured , Humans , Materials Testing , Osteoblasts/cytology , Polylactic Acid-Polyglycolic Acid Copolymer , Sheep
11.
Mund Kiefer Gesichtschir ; 5(5): 299-304, 2001 Sep.
Article in German | MEDLINE | ID: mdl-11693020

ABSTRACT

BACKGROUND: The preoperative manufacturing of individual skull implants using computer aided design (CAD) and computer aided manufacturing (CAM) is based on the use of titanium, although the use of other materials is also potentially possible. THE USE OF OTHER MATERIALS: The use of poly-(D,L-lactide) (PDLLA) as an implant material was investigated using an adult, formalin fixed sheep's head with a complex frontolateral defect. A standard individual titanium implant as well as a resection template made of aluminium were milled in order to allow bone resection and reconstruction within one operation. A mould was made of Teflon for the fabrication of the PDLLA implant using carbon dioxide at high pressure. This procedure allowed a critical comparison to be made of both implant materials and showed that the production of a biodegradable PDLLA implant is possible. At present the titanium implant is superior to the PDLLA implant, as PDLLA settled with slightly larger dimensions than the mould, although the structure itself was exact. DISCUSSION: The goal of the present research is the fabrication of a functionally graded material made of polylactide, polyglycolide, calcium phosphate and osteoinductive proteins using existing technology, which will meet all of the requirements for stability, resorption kinetics, biocompatibility, radiotranslucence and osteogenic potency of an ideal implant material.


Subject(s)
Bone Substitutes , Computer-Aided Design , Craniotomy , Polyesters , Prosthesis Implantation , Titanium , Humans , Microscopy, Electron, Scanning , Prosthesis Design , Prosthesis Fitting
12.
Eur J Drug Metab Pharmacokinet ; 26(1-2): 37-45, 2001.
Article in English | MEDLINE | ID: mdl-11554432

ABSTRACT

The stability of four major cytochrome P450 isoenzymes (CYPIA, CYP2B, CYP2E1 and CYP3A) and of two phase II conjugation enzymes (glucuronyl- and sulfotransferases) was investigated in primary cultures of rat, dog and human hepatocytes in the same conditions. 7-ethoxyresorufin deethylation (EROD), 7-methoxycoumarin demethylation (MCOD), chlorzoxazone (CLOX) 6-hydroxylation, 1'- and 4-hydroxylation of midazolam (MDZ), and p-nitrophenol glucuronidation and sulfation, were used respectively. The EROD activity was stable over 72 hours in rat and dog and only 48 hours in human hepatocytes. The MCOD activity was also stable in rat but decreased in dog by 30% within 72 hours The CLOX hydroxylase activity was most stable in human whereas in rat and dog it fell down to 30% within 72 and 24 hours, respectively. The MDZ hydroxylase activity showed the same unstability profile in the three species investigated. Both conjugation reactions were either stable or showed an increase by up to 60-70% in all three species over 72 hours. The enzymes tested showed different stabilities in rat, dog and human hepatocytes over 72 hours, thus demonstrating the limitations of hepatocyte monolayers as models for metabolic investigations and emphasising the need for validation/characterization studies before routine use.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Hepatocytes/enzymology , Animals , Cell Survival , Cells, Cultured , Dogs , Glucuronides/metabolism , Humans , Isoenzymes/metabolism , Male , Nitrophenols/metabolism , Rats , Sulfates/metabolism
13.
J Zoo Wildl Med ; 31(1): 77-81, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10884129

ABSTRACT

A 6-yr-old female Grevy's zebra (Equus grevyi) with a disseminated rhabditiform nematode infection is described. Antemortem clinical signs were limited to blindness and abnormal behavior believed to be caused by a recurrent nematode-induced uveitis. Histologic examination of the kidneys, heart, eyes, uterus, and lymph nodes revealed granulomas containing multiple sections of rhabditiform nematodes. Most of the recovered nematodes were larval stages with only a few adult females noted. The adults measured 243-297 microm x 11-16 microm (x = 269 x 14 microm). The distinctive rhabditiform esophagi had corpus:isthmus:bulb proportions of 19:11:5. On the basis of adult morphology, the nematode was identified as Halicephalobus gingivalis. This is the first report of this parasite in a zebra and indicates that this parasitic granulomatous disease should be considered in zebras with neurologic disease.


Subject(s)
Equidae/parasitology , Rhabditida Infections/veterinary , Animals , Blindness/parasitology , Blindness/pathology , Blindness/veterinary , Central Nervous System/pathology , Ciliary Body/parasitology , Ciliary Body/pathology , Eye Infections, Parasitic/parasitology , Eye Infections, Parasitic/pathology , Eye Infections, Parasitic/veterinary , Fatal Outcome , Female , Kidney/parasitology , Kidney/pathology , Lymph Nodes/parasitology , Lymph Nodes/pathology , Rhabditida/classification , Rhabditida/isolation & purification , Rhabditida Infections/parasitology , Rhabditida Infections/pathology , Uterus/parasitology , Uterus/pathology , Uveitis/parasitology , Uveitis/pathology , Uveitis/veterinary
14.
Vet Parasitol ; 90(4): 333-8, 2000 Jul 04.
Article in English | MEDLINE | ID: mdl-10856819

ABSTRACT

Two dogs, one from California and one from Arizona, were found to have aberrant infections caused by filarial nematodes of the genus Onchocerca. In both cases, the parasites are localized in or near the eye. In one case the worm was located in the cornea and was surgically removed. In the second case, a very marked granulomatous reaction was induced in the retrobulbar space, mimicking an abscess. This eye was enucleated. The worms in both instances were female, and were gravid, i.e. contained microfilariae in utero, indicating that a male worm(s) had been present and mating had occurred. The exact identity of the species of Onchocerca responsible cannot be determined, although the features observed are most like Onchocerca lienalis of cattle. These cases represent the fourth and fifth such cases reported from the US, and are especially interesting because of the unusual location of the worms, the small number of recognized cases, and the similarity to a recent zoonotic human infection.


Subject(s)
Dog Diseases/parasitology , Onchocerca/growth & development , Onchocerciasis, Ocular/veterinary , Animals , Arizona , California , Cornea/parasitology , Dog Diseases/surgery , Dogs , Eye Enucleation/veterinary , Female , Granuloma, Foreign-Body/parasitology , Granuloma, Foreign-Body/veterinary , Male , Onchocerciasis, Ocular/surgery
15.
J Exp Med ; 191(8): 1293-302, 2000 Apr 17.
Article in English | MEDLINE | ID: mdl-10770797

ABSTRACT

Using three different Fcgamma receptor (FcgammaR)-deficient mouse strains, we examined the induction of autoimmune hemolytic anemia by each of the four immunoglobulin (Ig)G isotype-switch variants of a 4C8 IgM antierythrocyte autoantibody and its relation to the contributions of the two FcgammaR, FcgammaRI, and FcgammaRIII, operative in the phagocytosis of opsonized particles. We found that the four IgG isotypes of this antibody displayed striking differences in pathogenicity, which were related to their respective capacity to interact in vivo with the two phagocytic FcgammaRs, defined as follows: IgG2a > IgG2b > IgG3/IgG1 for FcgammaRI, and IgG2a > IgG1 > IgG2b > IgG3 for FcgammaRIII. Accordingly, the IgG2a autoantibody exhibited the highest pathogenicity, approximately 20-100-fold more potent than its IgG1 and IgG2b variants, respectively, while the IgG3 variant, which displays little interaction with these FcgammaRs, was not pathogenic at all. An unexpected critical role of the low-affinity FcgammaRIII was revealed by the use of two different IgG2a anti-red blood cell autoantibodies, which displayed a striking preferential utilization of FcgammaRIII, compared with the high-affinity FcgammaRI. This demonstration of the respective roles in vivo of four different IgG isotypes, and of two phagocytic FcgammaRs, in autoimmune hemolytic anemia highlights the major importance of the regulation of IgG isotype responses in autoantibody-mediated pathology and humoral immunity.


Subject(s)
Immunoglobulin G/genetics , Immunoglobulin G/metabolism , Receptors, IgG/metabolism , Anemia, Hemolytic, Autoimmune/etiology , Anemia, Hemolytic, Autoimmune/genetics , Anemia, Hemolytic, Autoimmune/immunology , Animals , Autoantibodies/metabolism , Base Sequence , DNA Primers/genetics , Erythrocytes/immunology , Genetic Variation , Immunoglobulin Isotypes/genetics , Immunoglobulin Isotypes/metabolism , Immunoglobulin Switch Region/genetics , In Vitro Techniques , Iron/metabolism , Liver/metabolism , Liver/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout
16.
Eur J Immunol ; 30(2): 481-90, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10671203

ABSTRACT

Murine low-affinity receptors for IgG, FcgammaRII and FcgammaRIII, differ by their distinct capacities in mediating down-regulation or activation of cellular effector functions, respectively. In this study, antibodies detecting the mouse Ly-17.1 / 2 alloantigen system are demonstrated to be specific for FcgammaRII with no cross-reactivities to other FcgammaR, including FcgammaRIII. Using these FcgammaRII-specific monoclonal antibodies (mAb), the significance of FcgammaRII inhibition of FcgammaRIII was examined in two models of autoantibody [autoimmune hemolytic anemia (AIHA)]- and IgG immune complex-induced (Arthus reaction) inflammation in C57BL / 6 mice in comparison with FcgammaRII(- / -) and FcgammaRIII(- / -) mice. Our results demonstrate that both FcgammaRIII and FcgammaRII contributed to the binding of erythrocytes opsonized with the pathogenic IgG1 autoreactive anti-murine red blood cell antibody 105-2H. However, the functional blocking with anti-FcgammaRII mAb in C57BL / 6 mice and the lack of FcgammaRII expression in FcgammaRII(- / -) mice, which both lowered the threshold level of FcgammaRIII-triggered phagocytosis in vitro, did not results in enhanced disease development of 105-2H mAb-induced AIHA in vivo. This was in sharp contrast to cutaneous Arthus reaction, where FcgammaRIII-mediated activation was inhibited by FcgammaRII. Together these results show that murine AIHA is markedly different from other FcgammaR-dependent inflammatory diseases where FcgammaRIII is normally counterregulated by FcgammaRII.


Subject(s)
Anemia, Hemolytic/immunology , Arthus Reaction/immunology , Receptors, IgG/immunology , Anemia, Hemolytic/genetics , Animals , Antigen-Antibody Complex/immunology , Arthus Reaction/genetics , Autoantibodies/immunology , Down-Regulation , Gene Expression Regulation/immunology , Immunoglobulin G/immunology , Mice , Mice, Inbred C57BL , Receptors, IgG/genetics
17.
Eur J Pharm Sci ; 8(4): 255-60, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10425375

ABSTRACT

The flavin-containing monooxygenase (FMO)-dependent N-oxidation of benzydamine has been assessed as a method for monitoring the activity of FMOs in monolayer cultures of hepatocytes from rat, dog, rabbit, hamster and human. The advantage of this substrate is that benzydamine N-oxide formation can be measured directly in extracts of cellular incubations without an intensive work-up procedure. Benzydamine and its N-oxide are readily separated by HPLC with fluorometric detection. This assay proved sensitive enough to monitor FMOs activity in intact monolayer of cultured hepatocytes. The formation of benzydamine N-oxide was inhibited when hepatocytes were coincubated with methimazole (another FMO substrate) in a dose-dependent manner, whereas N-octylamine (an inhibitor of cytochrome P450) had no inhibitory effect. In contrast to cytochrome P450, FMO activity assessed by benzydamine N-oxidation was relatively stable for all species studied during 72-h cultures.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/metabolism , Benzydamine/metabolism , Liver/enzymology , Oxygenases/metabolism , Animals , Cells, Cultured , Cricetinae , Dogs , Enzyme Activation , Humans , Liver/cytology , Male , Mesocricetus , Oxidation-Reduction , Oxygenases/antagonists & inhibitors , Rabbits , Rats
18.
Drug Metab Dispos ; 27(1): 21-5, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9884305

ABSTRACT

The pharmacokinetics of the tumor necrosis factor receptorimmunoglobulin fusion protein, lenercept, were assessed in rats, rabbits, dogs and cynomolgus monkeys. Pharmacokinetic parameters were extrapolated to humans by allometric scaling. Lenercept was dosed i.v. at doses ranging from 0.1 to 5 mg/kg. Consistent with its all-human sequence, lenercept elicits an immune response in laboratory animals usually 6 to 10 days after dosing. The resulting period of more rapid clearance caused by the immune response was excluded from the pharmacokinetic evaluation. Lenercept showed a very low and similar clearance in all species tested (0. 0071-0.0097 ml.min/kg). The volume of distribution was estimated at values between 61 and 90 ml/kg, whereas the terminal half-life ranged from 3.4 days in rabbits to 6.5 days in rats. Thus, lenercept was characterized by similar pharmacokinetic properties across species, irrespective of their particular body weight. Accordingly, both clearance (ml/min) and volume of distribution (ml) scaled with an allometric exponent close to 1, whereas half-lives (including literature data in mice) yielded an allometric exponent close to 0. The predicted parameters in humans agree well with the observed values. Overall, the results demonstrate an allometric scaling for lenercept different from that for other therapeutic proteins, in that lenercept displays a similar pharmacokinetic behavior across species. Despite an early and pronounced immune response against this all-human protein in laboratory animals, the pharmacokinetic data were found to be predictive for humans, given that the more rapid immune-modulated clearance component in animals could be identified and excluded from the pharmacokinetic evaluation.


Subject(s)
Immunoglobulin G/metabolism , Immunoglobulin Heavy Chains , Receptors, Tumor Necrosis Factor/metabolism , Recombinant Fusion Proteins/metabolism , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Biological Availability , Dogs , Female , Half-Life , Immunoglobulin G/immunology , Immunoglobulin gamma-Chains , Macaca fascicularis , Male , Metabolic Clearance Rate , Rabbits , Rats , Receptors, Tumor Necrosis Factor/immunology , Recombinant Fusion Proteins/immunology , Retrospective Studies
19.
Blood ; 92(11): 3997-4002, 1998 Dec 01.
Article in English | MEDLINE | ID: mdl-9834201

ABSTRACT

In autoimmune hemolytic anemia (AIHA), there is accumulating evidence for an involvement of FcgammaR expressed by phagocytic effector cells, but demonstration of a causal relationship between individual FcgammaRs and IgG isotypes for disease development is lacking. Although the relevance of IgG isotypes to human AIHA is limited, we could show a clear IgG isotype dependency in murine AIHA using pathogenic IgG1 (105-2H) and IgG2a (34-3C) autoreactive anti-red blood cell antibodies in mice defective for FcgammaRIII, and comparing the clinical outcome to those in wild-type mice. FcgammaRIII-deficient mice were completely resistent to the pathogenic effects of 105-2H monoclonal antibody, as shown by a lack of IgG1-mediated erythrophagocytosis in vitro and in vivo. In addition, the IgG2a response by 34-3C induced a less severe but persistent AIHA in FcgammaRIII knock-out mice, as documented by a decrease in hematocrit. Blocking studies indicated that the residual anemic phenotype induced by 34-3C in the absence of FcgammaRIII reflects an activation of FcgammaRI that is normally coexpressed with FcgammaRIII on macrophages. Together these results show that the pathogenesis of AIHA through IgG1-dependent erythrophagocytosis is exclusively mediated by FcgammaRIII and further suggest that FcgammaRI, in addition to FcgammaRIII, contributes to this autoimmune disease when other IgG isotypes such as IgG2a are involved.


Subject(s)
Anemia, Hemolytic, Autoimmune/immunology , Erythrocytes/immunology , Immunoglobulin G/immunology , Receptors, IgG/deficiency , Animals , Autoantibodies/immunology , Cytotoxicity, Immunologic , Humans , Immunoglobulin Isotypes/immunology , Mice , Mice, Knockout , Phagocytosis , Receptors, IgG/genetics , Receptors, IgG/immunology
20.
Bone ; 22(4): 341-6, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9556133

ABSTRACT

In mouse bone marrow cultures, the formation of osteoclast-like, that is, tartrate-resistant acid phosphatase-positive (TRAP+) and calcitonin (CT) receptor-positive multinucleated cells (MNCs), induced by 10(-10) to 10(-8) mol/L 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3], could be augmented by triiodothyronine (T3), which alone had no effect on osteoclast-like cell formation. The permissive effect of T3 increased the response to 1alpha,25(OH)2D3 by approximately one order of magnitude. Linear concentration dependence was observed between 10(-11) and 10(-8) mol/L T3. Importantly, inhibition of prostaglandin synthesis by indomethacin significantly impeded osteoclast-like cell formation by 1alpha,25(OH)2D3 and abrogated the effect of T3 thereon. Basal interleukin-6 (IL-6) production by cultured marrow cells was significantly stimulated by 1alpha,25(OH)2D3. However, even at an exceedingly high concentration of 20 ng/mL, IL-6 was ineffective in inducing osteoclast-like cell formation. Therefore, any hormonally induced rise in IL-6 release from bone marrow cells could not account for the observed changes in TRAP+ MNC numbers. Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody. Unimpaired signaling through the IL-6/IL-6R system is also a prerequisite for the auxiliary effect of T3 on induction of osteoclast-like cells by 1alpha,25(OH)2D3. Our data provide evidence that 1alpha,25(OH)2D3 induces osteoclast-like cell formation, at least in part, in an IL-6-dependent mode of action, which is also subject to modulation by T3. The mechanism of interaction of the two hormones apparently involves joint stimulation of prostaglandin synthesis.


Subject(s)
Bone Marrow Cells/drug effects , Calcitriol/pharmacology , Interleukin-6/metabolism , Osteoclasts/cytology , Triiodothyronine/pharmacology , Acid Phosphatase/analysis , Animals , Antibodies, Monoclonal/pharmacology , Bone Marrow Cells/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Drug Synergism , Giant Cells/cytology , Hematopoiesis/drug effects , Immunohistochemistry , Interleukin-6/immunology , Isoenzymes/analysis , Mice , Mice, Inbred BALB C , Prostaglandins/biosynthesis , Receptors, Calcitonin/analysis , Tartrate-Resistant Acid Phosphatase
SELECTION OF CITATIONS
SEARCH DETAIL